Sino Biopharmaceutical
(OTC) SBHMY
Sino Biopharmaceutical Financials at a Glance
Market Cap
$14.21B
Revenue (TTM)
$30.57B
Net Income (TTM)
$3.87B
EPS (TTM)
$0.57
P/E Ratio
27.74
Dividend
$0.23
Beta (Volatility)
0.07 (Low)
Dividend
$0.23
Beta (Volatility)
0.07 (Low)
Price
$15.89
Volume
17
Open
$15.78
Price
$15.89
Volume
17
Open
$15.78
Previous Close
$15.89
Daily Range
$15.78 - $15.89
52-Week Range
$8.76 - $20.16
Dividend
$0.23
Beta (Volatility)
0.07 (Low)
Price
$15.89
Volume
17
Open
$15.78
Previous Close
$15.89
Daily Range
$15.78 - $15.89
52-Week Range
$8.76 - $20.16
SBHMY News
SBHMY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sino Biopharmaceutical
Industry
Pharmaceuticals
Sector
Health CareEmployees
24,379
CEO
S Y Tse
Website
www.sinobiopharm.comHeadquarters
Wan Chai, HK
SBHMY Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
20%
Net Income Margin
13%
Return on Equity
12%
Return on Capital
12%
Return on Assets
5%
Earnings Yield
3.60%
Dividend Yield
0.01%
Payout Ratio
0.00%
Stock Overview
Market Cap
$14.21B
Shares Outstanding
894.28M
Volume
17
Short Interest
0.00%
Avg. Volume
17.148
Financials (TTM)
Gross Profit
$23.53B
Operating Income
$6.14B
EBITDA
$6.11B
Operating Cash Flow
$6.62B
Capital Expenditure
$1.39B
Free Cash Flow
$5.22B
Cash & ST Invst.
$14.60B
Total Debt
$9.78B
Sino Biopharmaceutical Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$8.79B
+10.7%
Gross Profit
$7.25B
+11.2%
Gross Margin
82.47%
N/A
Market Cap
$14.21B
N/A
Market Cap/Employee
$582.89K
N/A
Employees
24,379
N/A
Net Income
$1.69B
+12.3%
EBITDA
$1.98B
+0.1%
Quarterly Fundamentals
Net Cash
$7.87B
+124.6%
Accounts Receivable
$8.15B
+11.7%
Inventory
$2.10B
+14.5%
Long Term Debt
$3.08B
+164.7%
Short Term Debt
$8.87B
+4.2%
Return on Assets
5.17%
N/A
Return on Invested Capital
12.29%
N/A
Free Cash Flow
$0.00
-100.0%
Operating Cash Flow
$0.00
-100.0%